{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yang Z"],"funding":["National Natural Science Foundation of China (National Science Foundation of China)"],"pagination":["56"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10925604"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["Adding PD-1 blockade in the neoadjuvant regimens for locally advanced rectal cancer (LARC) patients with microsatellite stable (MSS) / mismatch repair-proficient (pMMR) tumors is an attractive, but debatable strategy. This phase 2, multicenter, prospective, single-arm study enrolled patients from 6 centers from June 2021 to November 2022. Locally advanced rectal cancer (LARC, cT<sub>3-4a</sub>N<sub>0</sub>M<sub>0</sub> and cT<sub>1-4a</sub>N<sub>1-2</sub>M<sub>0</sub>) patients aged ≥18 years with the distance from distal border of tumor to anal verge ≤10 cm (identified by Magnetic Resonance Imaging) were qualified for inclusion. The patients received long-course radiotherapy (50 Gy/25 fractions, 2 Gy/fraction, 5 days/week) and three 21-day cycles capecitabine (850-1000 mg/m2, bid, po, day"],"journal":["Signal transduction and targeted therapy"],"pubmed_title":["Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study."],"pmcid":["PMC10925604"],"funding_grant_id":["82202884"],"pubmed_authors":["Zhang J","Xu R","Chen G","Gao J","Bai Z","Sun Y","Zheng J","Liu Y","Yang Z","Zhang Z","He W","Zhang X","Li A","Han J","Yao H","Deng W","Liu G"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.","description":"Adding PD-1 blockade in the neoadjuvant regimens for locally advanced rectal cancer (LARC) patients with microsatellite stable (MSS) / mismatch repair-proficient (pMMR) tumors is an attractive, but debatable strategy. This phase 2, multicenter, prospective, single-arm study enrolled patients from 6 centers from June 2021 to November 2022. Locally advanced rectal cancer (LARC, cT<sub>3-4a</sub>N<sub>0</sub>M<sub>0</sub> and cT<sub>1-4a</sub>N<sub>1-2</sub>M<sub>0</sub>) patients aged ≥18 years with the distance from distal border of tumor to anal verge ≤10 cm (identified by Magnetic Resonance Imaging) were qualified for inclusion. The patients received long-course radiotherapy (50 Gy/25 fractions, 2 Gy/fraction, 5 days/week) and three 21-day cycles capecitabine (850-1000 mg/m2, bid, po, day","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-06-02T11:22:20.493Z","creation":"2024-11-20T19:07:24.859Z"},"accession":"S-EPMC10925604","cross_references":{"pubmed":["38462629"],"doi":["10.1038/s41392-024-01762-y"]}}